Xtl Biopharma Ads (XTLB) 1.00 $XTLB XTL

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Xtl Biopharma Ads (XTLB) 1.00 $XTLB

XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1
PR Newswire - Thu Aug 11, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has filed a new patent application with the U.S. Patent and Trademark Office to protect doses of hCDR1 lower than 0.5 mg weekly, in the treatment of Systemic Lupus Erythematosus (SLE).
XTLB: 1.00 (+0.03)

Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.00 (+0.03), TEVA: 51.22 (+0.32), GSK: 44.26 (+1.28)

XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update
PR Newswire - Wed Jun 01, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the three months ended March 31, 2016 and provided an update on the development program for its lead drug candidate hCDR1 in the treatment of Systemic Lupus Erythematosus (SLE).
XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016
PR Newswire - Mon May 16, 10:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, announced today the Company's CEO Josh Levine will be presenting at the ChinaBio® Partnering Forum in Suzhou, China on Thursday, May 19, 2016 at 2:00 PM.
XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update
PR Newswire - Thu Mar 31, 8:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the year ended December 31, 2015 and provided an update on the development program for its lead drug candidate hCDR1.
XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
PR Newswire - Wed Feb 10, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that its lead drug candidate hCDR1 has been granted a patent by the Israel Patent Office. The patent, titled "Pharmaceutical Compositions Comprising a Peptide and a Substituted ß Cyclodextrin for use in Treating Systemic Lupus Erythematosus and Processes for their Manufacture," addresses the pharmaceutical composition of hCDR1 and its manufacturing processes. The compound hCDR1 and its formulations have been previously granted patents in numerous key jurisdictions including the U.S., Europe, Israel, Japan, China, India, Russia, Australia and Canada.
XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America
PR Newswire - Wed Jan 27, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has accepted the Lupus Foundation of America's (LFA) invitation to join the foundation's Corporate Advisory Council (CAC) as of January 2016.
XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE).
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

Cellect Biomed Announces Key Leadership Changes
GlobeNewswire - Mon Nov 09, 7:30AM CST
Cellect Biomed Ltd. (TASE:CLBD) ("Cellect" or the "Company", a developer of innovative technology which enables the functional selection of stem cells, announced additions to its management and professional teams in support of its preparations for the commencement of human clinical trials and its planned dual-listing on a U.S. stock exchange.
XTLB: 1.00 (+0.03), ORPN: 1.68 (unch)

XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany.
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda" to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York.
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015.
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03), NVS: 79.38 (+1.11)

XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets
PR Newswire - Mon Jun 01, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that following an evaluation of the market opportunity for it pipeline products, the Company has decided to focus its efforts and expenditures exclusively on its two core assets: hCDR1 for the treatment of SLE/lupus and rHuEPO for "no-option" multiple myeloma patients. XTL also provided its financial and operational results for the first quarter ended March 31, 2015.
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics
PR Newswire - Mon May 18, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SYPR: 1.05 (-0.01), TANH: 3.36 (-0.03), ADMA: 5.79 (+0.02), XTLB: 1.00 (+0.03)

XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference
PR Newswire - Mon May 11, 10:59AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the company will present at the IATI Biomed 2015 Conference on May 12, 2015:
XTL: 63.98 (+0.41), XTLB: 1.00 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading